Détail d'une personne de l'annuaire - fr | Cancéropôle Est, la recherche innovante dans la lutte contre le cancer

Prognostic value of postinduction medullary myeloid recovery by flow cytometry in acute myeloid leukemia.

Row C, Lechevalier N, Vial JP, Mimoun A, Bastie JN, Lafon I, Pigneux A, Leguay T, Callanan M, Maynadie M, Béné MC, Dumas PY, Guy J

EJHaem. 2024 02;5(1):84-92

Glycemic control in people with diabetes treated with cancer chemotherapy: contribution of continuous glucose monitoring.

Legris P, Bouillet B, Pâris J, Pistre P, Devaux M, Bost S, Simoneau I, Manfredi S, Drouillard A, Bastie JN, Chaix M, Massoud P, Rouland A, Aho S, Boulin M, Petit JM

Acta Diabetol. 2023 01 13;:

Influence of Sociodemographic Determinants on the Hodgkin Lymphoma Baseline Characteristics in Long Survivors Patients Enrolled in the Prospective Phase 3 Trial AHL2011.

Chevreux S, de Barros S, Laurent C, Durand A, Delpierre C, Robert P, Joubert C, Griolet S, Kanoun S, Bastie JN, Casasnovas RO, Rossi C

Cancers (Basel). 2022 12 22;15(1):

Protein Arginine Methyltransferases as Therapeutic Targets in Hematological Malignancies.

Sauter C, Simonet J, Guidez F, Dumétier B, Pernon B, Callanan M, Bastie JN, Aucagne R, Delva L

Cancers (Basel). 2022 11 5;14(21):

Clinical and Economic Impact of a Multidisciplinary Follow-Up Program in Lymphoma Patients.

Devaux M, Boulin M, Mounier M, Caillot D, Ahwij N, Herbin A, Bastie JN, Favennec C, Robert P, Pistre P, Bost S, Amiot P, Jacquesson L, Casasnovas O, Rossi C, Gueneau P

Cancers (Basel). 2022 05 21;14(10):

Early achievement of measurable residual disease negativity in the treatment of multiple myeloma as predictor of outcome.

Baumelou M, Payssot A, Row C, Racine J, Lafon I, Bastie JN, Chevreux S, Chrétien ML, Maynadié M, Caillot D, Guy J

Br J Haematol. 2022 Mar 11;:

Identification of novel, clonally stable, somatic mutations targeting transcription factors PAX5 and NKX2-3, the epigenetic regulator LRIF1, and BRAF in a case of atypical B-cell chronic lymphocytic leukemia harboring a t(14;18)(q32;q21).

Burlet B, Ramla S, Fournier C, Abrey-Recalde MJ, Sauter C, Chrétien ML, Rossi C, Duffourd Y, Ragot S, Buriller C, Tournier B, Chapusot C, Nadal N, Racine J, Guy J, Bailly F, Martin L, Casasnovas O, Bastie JN, Caillot D, Albuisson J, Broccardo C, Thieblemont C, Delva L, Maynadié M, Aucagne R, Callanan MB

Cold Spring Harb Mol Case Stud. 2021 Feb;7(1):

Oxaliplatin-Induced Evans Syndrome: A Possible Dual Mechanism.

Rousseau C, Nguyen TN, Rebibou JM, Bastie JN, Audia S, Darut-Jouve A, Legendre M

Clin Colorectal Cancer. 2019 Nov 26;:

T-cell acute lymphoblastic leukemia displays autocrine production of Interleukin-7.

Buffière A, Uzan B, Aucagne R, Hermetet F, Mas M, Nassurdine S, Aznague A, Carmignac V, Tournier B, Bouchot O, Ballerini P, Barata JT, Bastie JN, Delva L, Pflumio F, Quéré R

Oncogene. 2019 Aug 15;:

Serpin B1 defect and increased apoptosis of neutrophils in Cohen syndrome neutropenia.

Duplomb L, Rivière J, Jego G, Da Costa R, Hammann A, Racine J, Schmitt A, Droin N, Capron C, Gougerot-Pocidalo MA, Dubrez L, Aral B, Lafon A, Edery P, Ghoumid J, Blair E, El Chehadeh-Djebbar S, Carmignac V, Thevenon J, Guy J, Girodon F, Bastie JN, Delva L, Faivre L, Thauvin-Robinet C, Solary E

J. Mol. Med.. 2019 Mar 7;:

High-fat diet disturbs lipid raft/TGF-β signaling-mediated maintenance of hematopoietic stem cells in mouse bone marrow.

Hermetet F, Buffière A, Aznague A, Pais de Barros JP, Bastie JN, Delva L, Quéré R

Nat Commun. 2019 Jan 31;10(1):523

[New therapeutic strategies in non-Hodgkin lymphomas and Hodgkin lymphoma].

Rossi C, Bastie JN

Rev Med Interne. 2018 May 22;:

HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis.

Sevin M, Kubovcakova L, Pernet N, Causse S, Vitte F, Villeval JL, Lacout C, Cordonnier M, Rodrigues-Lima F, Chanteloup G, Mosca M, Chrétien ML, Bastie JN, Audia S, Sagot P, Ramla S, Martin L, Gleave M, Mezger V, Skoda R, Plo I, Garrido C, Girodon F, de Thonel A

Nat Commun. 2018 Apr 12;9(1):1431

Saracatinib impairs maintenance of human T-ALL by targeting the LCK tyrosine kinase in cells displaying high level of lipid rafts.

Buffière A, Accogli T, Saint-Paul L, Lucchi G, Uzan B, Ballerini P, Bastie JN, Delva L, Pflumio F, Quéré R

Leukemia. 2018 Feb 28;:

Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO).

Godet S, Protin C, Dupuis J, Dartigeas C, Bastie JN, Herbaux C, Leblond V, de Guibert S, Ghez D, Brion A, Ysebaert L, Delmer A, Quinquenel A

Am. J. Hematol.. 2018 Feb;93(2):E52-E54

Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study.

Desjonquères A, Chevallier P, Thomas X, Huguet F, Leguay T, Bernard M, Bay JO, Tavernier E, Charbonnier A, Isnard F, Hunault M, Turlure P, Renaud M, Bastié JN, Himberlin C, Lepretre S, Lioure B, Lhéritier V, Asnafi V, Beldjord K, Lafage-Pochitaloff M, Béné MC, Ifrah N, Dombret H

Blood Cancer J. 2016 Dec;6(12):e504

[CD45 phosphatase, a relevant target for the treatment of acute myeloid leukemia].

Saint-Paul L, Nguyen CH, Bastie JN, Delva L, Quéré R

Med Sci (Paris). 2016 Dec;32(12):1051-1053

CD45 phosphatase is crucial for human and murine acute myeloid leukemia maintenance through its localization in lipid rafts.

Saint-Paul L, Nguyen CH, Buffière A, Pais de Barros JP, Hammann A, Landras-Guetta C, Filomenko R, Chrétien ML, Johnson P, Bastie JN, Delva L, Quéré R

Oncotarget. 2016 10;7(40):64785-64797

Emergency and elective pulmonary surgical resection in haematological patients with invasive fungal infections: a report of 50 cases in a single centre.

Chretien ML, Legouge C, Pagès PB, Lafon I, Ferrant E, Plocque A, Favennec C, Estivalet L, Bottolier-Lemallaz E, Dalle F, Bastie JN, Bernard A, Caillot D

Clin. Microbiol. Infect.. 2016 Sep;22(9):782-787

A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.

Thépot S, Ben Abdelali R, Chevret S, Renneville A, Beyne-Rauzy O, Prébet T, Park S, Stamatoullas A, Guerci-Bresler A, Cheze S, Tertian G, Choufi B, Legros L, Bastié JN, Delaunay J, Chaury MP, Sanhes L, Wattel E, Dreyfus F, Vey N, Chermat F, Preudhomme C, Fenaux P, Gardin C,

Haematologica. 2016 Aug;101(8):918-25

Trim33/Tif1γ is involved in late stages of granulomonopoiesis in mice.

Chrétien ML, Legouge C, Martin RZ, Hammann A, Trad M, Aucagne R, Largeot A, Bastie JN, Delva L, Quéré R

Exp. Hematol.. 2016 Aug;44(8):727-739.e6

Evolution of procalcitonin, C-reactive protein and fibrinogen levels in neutropenic leukaemia patients with invasive pulmonary aspergillosis or mucormycosis.

Roques M, Chretien ML, Favennec C, Lafon I, Ferrant E, Legouge C, Plocque A, Golfier C, Duvillard L, Amoureux L, Bastie JN, Maurin-Bernier L, Dalle F, Caillot D

Mycoses. 2016 Jun;59(6):383-90

The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.

Olombel G, Guerin E, Guy J, Perrot JY, Dumezy F, de Labarthe A, Bastie JN, Legrand O, Raffoux E, Plesa A, Wagner-Ballon O, Cornet E, Salaun V, Preudhomme C, Thomas X, Pautas C, Chantepie S, Turlure P, Castaigne S, Dombret H, Feuillard J

Blood. 2016 Apr;127(17):2157-60

De-escalation chemotherapy and hematological profiles in patients with advanced Hodgkin's lymphoma.

Seignez A, Casasnovas O, Ferrant E, Bastie JN, Mondoloni P, Aho LS, Boulin M

Int J Clin Pharm. 2015 Dec;37(6):1033-7

Detection of the CALR mutation in the diagnosis of splanchnic vein thrombosis.

Roques M, Park JH, Minello A, Bastie JN, Girodon F

Br J Haematol. 2015 May;169(4):601-3

Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study.

Dupuis J, Morschhauser F, Ghesquières H, Tilly H, Casasnovas O, Thieblemont C, Ribrag V, Bossard C, Le Bras F, Bachy E, Hivert B, Nicolas-Virelizier E, Jardin F, Bastie JN, Amorim S, Lazarovici J, Martin A, Coiffier B

Lancet Haematol. 2015 Apr;2(4):e160-5

[A novel mouse model to study physiological aging of haematopoietic cells].

Quere R, Bastie JN, Delva L

Med Sci (Paris). 2014 Dec;30(12):1076-8

[A rare cause of pulmonary opacities: Lung localization of Waldenstrom's macroglobulinemia].

Monnet CM, Favrolt N, Bastie JN, Chretien ML, Benoit F, Rossi C, Camus P, Bonniaud P

Rev Mal Respir. 2014 Sep;31(7):632-5

Tif1gamma regulates the TGF-beta1 receptor and promotes physiological aging of hematopoietic stem cells.

Quere R, Saint-Paul L, Carmignac V, Martin RZ, Chretien ML, Largeot A, Hammann A, Pais de Barros JP, Bastie JN, Delva L

Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):10592-7

Perforation of bowel lymphoma: beware of atypical presentations.

Lagoutte N, Doussot A, Leung U, Facy O, Bastie JN, Rat P, Ortega-Deballon P

J Gastrointest Cancer. 2014 Jun;45(2):121-5

Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.

Rossi C, Kanoun S, Berriolo-Riedinger A, Dygai-Cochet I, Humbert O, Legouge C, Chretien ML, Bastie JN, Brunotte F, Casasnovas RO

J Nucl Med. 2014 Apr;55(4):569-73

The reversed halo sign: pathognomonic pattern of pulmonary mucormycosis in leukemic patients with neutropenia?

Legouge C, Caillot D, Chrétien ML, Lafon I, Ferrant E, Audia S, Pagès PB, Roques M, Estivalet L, Martin L, Maitre T, Bastie JN, Dalle F

Clin. Infect. Dis.. 2014 Mar;58(5):672-8

Symplekin, a polyadenylation factor, prevents MOZ and MLL activity on HOXA9 in hematopoietic cells.

Largeot A, Paggetti J, Broseus J, Aucagne R, Lagrange B, Martin RZ, Berthelet J, Quere R, Lucchi G, Ducoroy P, Bastie JN, Delva L

Biochim Biophys Acta. 2013 Dec;1833(12):3054-63

A role for miR-142-3p in colony-stimulating factor 1-induced monocyte differentiation into macrophages.

Lagrange B, Martin RZ, Droin N, Aucagne R, Paggetti J, Largeot A, Itzykson R, Solary E, Delva L, Bastie JN

Biochim Biophys Acta. 2013 Aug;1833(8):1936-46

[MiR-142-3p in leukaemogenesis: tumour suppressor or oncomiR?].

Lagrange B, Martin RZ, Droin N, Solary E, Bastie JN, Delva L

Med Sci (Paris). 2013 Jun-Jul;29(6-7):574-6

[Evaluation of the new Hevylite IgA assay for the diagnosis and follow-up of monoclonal gammopathies].

Lakomy D, Lemaire-Ewing S, Denimal D, Bastie JN, Lafon I, Caillot D

Ann Biol Clin (Paris). 2013 Mar-Apr;71(2):157-63

Heterogeneity of molecular markers in chronic myelomonocytic leukemia: a disease associated with several gene alterations.

Bastie JN, Aucagne R, Droin N, Solary E, Delva L

Cell Mol Life Sci. 2012 Sep;69(17):2853-61

[TIF1gamma: a tumor suppressor gene in chronic myelomonocytic leukemia].

Aucagne R, Droin N, Solary E, Bastie JN, Delva L

Med Sci (Paris). 2011 Aug-Sep;27(8-9):696-8

Transcription intermediary factor 1gamma is a tumor suppressor in mouse and human chronic myelomonocytic leukemia.

Aucagne R, Droin N, Paggetti J, Lagrange B, Largeot A, Hammann A, Bataille A, Martin L, Yan KP, Fenaux P, Losson R, Solary E, Bastie JN, Delva L

J Clin Invest. 2011 Jun 1;121(6):2361-70

Crosstalk between leukemia-associated proteins MOZ and MLL regulates HOX gene expression in human cord blood CD34+ cells.

Paggetti J, Largeot A, Aucagne R, Jacquel A, Lagrange B, Yang XJ, Solary E, Bastie JN, Delva L

Oncogene. 2010 Sep 9;29(36):5019-31

TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.

Kosmider O, Gelsi-Boyer V, Ciudad M, Racoeur C, Jooste V, Vey N, Quesnel B, Fenaux P, Bastie JN, Beyne-Rauzy O, Stamatoulas A, Dreyfus F, Ifrah N, de Botton S, Vainchenker W, Bernard OA, Birnbaum D, Fontenay M, Solary E

Haematologica. 2009 Dec;94(12):1676-81

MOZ/TIF2-induced acute myeloid leukaemia in transgenic fish.

Zhuravleva J, Paggetti J, Martin L, Hammann A, Solary E, Bastie JN, Delva L

Br J Haematol. 2008 Nov;143(3):378-82

A role for the transcription intermediary factor 2 in zebrafish myelopoiesis.

Zhuravleva J, Solary E, Chluba J, Bastie JN, Delva L

Exp Hematol. 2008 May;36(5):559-67

[Splenomegaly].

Bastie JN

Rev Prat. 2006 Dec 31;56(20):2271-4.

Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study.

Abgrall JF, Guibaud I, Bastie JN, Flesch M, Rossi JF, Lacotte-Thierry L, Boyer F, Casassus P, Slama B, Berthou C, Rodon P, Leporrier M, Villemagne B, Himberlin C, Ghomari K, Larosa F, Rollot F, Dugay J, Allard C, Maigre M, Isnard F, Zerbib R, Cauvin JM

Haematologica. 2006 Aug;91(8):1027-32.